impact factor
logo
 

Review

 

Disease activity indices in systemic sclerosis: a systematic literature review


1, 2, 3, 4, 5, 6

 

  1. Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University, Belgium. karin.melsens@ugent.be
  2. Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University; and Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University, Belgium.
  3. Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University, Belgium.
  4. Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University, Belgium.
  5. Department of Cardiology, Ghent University Hospital, Belgium.
  6. Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University; and Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University, Belgium.

CER9058
2016 Vol.34, N°5 ,Suppl.100
PI 0186, PF 0192
Review

Free to view
(click on article PDF icon to read the article)

PMID: 27385265 [PubMed]

Received: 19/10/2015
Accepted : 18/05/2016
In Press: 06/07/2016
Published: 13/10/2016

Abstract

OBJECTIVES:
Reviewing disease activity indices (DAI) in systemic sclerosis (SSc) and reporting their validation status.
METHODS:
Literature was systematically reviewed on studies documenting the development of DAI, assessing the validation status of DAI and studies using a DAI in their analysis. The qualitative and quantitative validation status of existing DAI was assessed based on OMERACT and on definitions of the American College of Rheumatology (ACR) committee on quality measures.
RESULTS:
Three DAI in SSc have been proposed in literature: the European Scleroderma Study Group (EScSG) activity index, the 12-point DAI and the Combined Response Index for Systemic Sclerosis (CRISS). The EScSG activity index is yet applied as an outcome measure in 48 different studies. The EScSG activity index and the CRISS are provisional partially validated DAI.
CONCLUSIONS:
Future studies are needed to fully validate the EScSG activity index and the CRISS and to assess the validation status of the 12-point DAI.

Rheumatology Article

Rheumatology Addendum